Novel serum nucleosomics biomarkers for the detection of colorectal cancer

Anticancer Research

Volumn 34, Issue 5, 2014, Pages 2357-2362

  Holdenrieder, Stefan ^a,d   Dharuman, Yoganiranjana ^a   Standop, Jens ^a   Trimpop, Nicolai ^a   Herzog, Marielle ^b   Hettwer, Karina ^c,d   Simon, Kirsten ^c,d   Uhlig, Steffen ^c,d   Micallef, Jake ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Belgian Volition SA   (Belgium)

^c QuoData Quality amp Statistics   (Germany)

^d Joint Research and Services Center for Biomarker Evaluation in Oncology   (Germany)

Author keywords

Colorectal cancer; Diagnosis; DNA methylation; Nucleosomics; Serum

Indexed keywords

5 METHYLCYTOSINE; BIOLOGICAL MARKER; DNA; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL EVALUATION; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; DNA MODIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC VARIABILITY; GENOMICS; HUMAN; NUCLEOSOME; NUCLEOSOMICS; OPTICAL DENSITY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SERUM; VALIDATION STUDY; AREA UNDER THE CURVE; BLOOD; COLORECTAL TUMOR; DIAGNOSIS; EARLY DIAGNOSIS; METHODOLOGY; REPRODUCIBILITY;

COLORECTAL CANCER; DIAGNOSIS; DNA METHYLATION; NUCLEOSOMICS; SERUM;

AREA UNDER CURVE; COLORECTAL NEOPLASMS; DNA; DNA METHYLATION; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NUCLEOSOMES; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84902957423     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Siegel R, Naishadham D and Jemal A: Cancer Statistics 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C and Hoffmeister M: Reduced risk of colorectal cancer up to 10 years after screening, surveillance or diagnostic colonoscopy. Gastroenterol 146: 709-717, 2014.
3. Kuipers EJ, Rösch T and Bretthauer M: Colorectal cancer screening-optimizing current strategies and new directions. Nat Rev Clin Oncol 10: 130-142, 2013.
4. Beachy SH and Repasky EA: Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother 57: 759-775, 2008.
5. Esteller M: Epigenetics in cancer. N Engl J Med 358: 1148-1159, 2008.
6. Hatziapostolou M and Iliopoulos D: Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 68: 1681-1702, 2011.
7. Füllgrabe J, Kavanagh E and Joseph B: Histone onco-modifications. Oncogene 30: 3391-3403, 2011.
8. Summers T, Langan RC, Nissan A, Brücher B, Bilchik AJ, Protic M, Daumer M, Avital I and Stojadinovic A: Serum-based DNA methylation biomarkers in colorectal cancer: potential for screening and early detection. J Cancer 4: 210-216, 2013.
9. Van Engeland M, Derks S, Smits KM, Meijer GA and Herman JG: Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 29: 1382-1391, 2011.
10. Holdenrieder S, Stieber P, Bodenmueller H, Fertig G, Fuerst H, Schmeller N, Untch M and Seidel D: Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med 39: 596-605, 2001.
11. Elshimali YI, Khaddour H, Sarkissyan M, Wu Y and Vadgama JV: The clinical utilization of circulating cell-free DNA (ccfDNA) in blood of cancer patients. Int J Mol Sci 14: 18925-18958, 2013.
12. Hufnagl C, Stocher M, Moik M, Geisberger R and Greil R: A modified phenol-chloroform extraction method for isolating circulating cell-free DNA of tumor patients. J Nuc Acids Inv 4: 1-3, 2013.
13. Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, v Pawel J, Raith H, Feldmann K, Kremer A, Müller S, Geiger S, Hamann GF, Seidel D and Stieber P: Clinical relevance of circulating nucleosomes in cancer disease. Ann NY Acad Sci 1137: 180-189, 2008.
14. Levenson VV: DNA methylation as a universal biomarker. Expert Rev Mol Diagn 10: 481-488, 2010.
15. Zhai R, Zhao Y, Su L, Cassidy L, LiuG and Christiani DC: Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus. Neoplasia 14: 29-33, 2012.
16. Jin H, Ma Y, Shen Q and Wang X: Circulating methylated DNA as biomarkers for cancer detection. In: Methylation-from DNA, RNA and Histones to Diseases and Treatment. Dricu A (ed.), InTech, Rijeka, pp. 137-152, 2013.
17. deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, Steiger KV, Grützmann R, Pilarsky C, Habermann JK, Fleshner PR, Oubre BM, Day R, Sledziewski AZ and Lofton-Day C: Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55: 1337-1346, 2009.
18. Deligezer U, Akisik EE, Erten N and Dalay N: Sequence-specific histone methylation is detectable on circulating nucleosomes in plasma. Clin Chem 54: 1125-1131, 2008.
19. Leszinski G, Gezer U, Siegele B, Stoetzer O and Holdenrieder S: Relevance of histone marks H3K9me3 and H4K20me3 in cancer. Anticancer Res 32: 2199-2205, 2012.
20. Gezer U, Ustek D, Yörüker EE, Cakiris A, Abaci N, Leszinski G, Dalay N and Holdenrieder S: Characterization of H3K9me3-And H4K20me3-Associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer. Tumour Biol 34: 329-336, 2013.
21. Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N, Tangkijvanich P, Thong-ngam D, Voravud N, Sriuranpong V and Mutirangura A: Distinctive pattern of LINE1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 23: 8841-8846, 2004.
22. Brennan K and Flanagan JM: Is there a link between genome-wide hypomethylation in blood and cancer risk? Cancer Prev Res 5: 1345-1354, 2012.
23. Pufulete M, Al-Ghnaniem R, Leather AJM, Appleby P, Gout S, Terry C, Emery PW and Sanders TAB: Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case-control study. Gastroenterol 124: 1240-1248, 2003.
24. Lim U, Flood A, Choi S, Albanes D, Cross AJ, Schatzkin A, Sinha R, Katki HA, Cash B, Schoenfeld P and Stolzenberg-Solomon R: Genomic methylation of leukocyte DNA in relation to colorectal adenoma among asymptomatic women. Gastroenterol 134: 47-55, 2008.
25. Feinberg AP and Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89-92, 1983.
26. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, Ji H, Potash JB, Sabunciyan S and Feinberg AP: The human colon cancer methylome shows similar hypo-And hypermethylation at conserved tissue-specific CpG island shores. Nature Genetics 41: 178-86, 2009.
27. Grimm G, Chavez L, Vilardell M, Farrall AL, Tierling S, Bohm JW, Grote P, Lienhard M, Dietrich J, Timmermann B, Walter J, Schweiger MR, Lehrach H, Herwig R, Herrmann BG and Morkel M: DNA-methylome analysis of mouse intestinal adenoma identifies a tumour-specific signature that is partly conserved in human colon cancer. PLOS Genetics 9: 1-14, 2013.
28. Bardhan K and Liu K: Epigenetics and colorectal cancer pathogenesis. Cancers 5: 676-713, 2013.
29. Rodriguez-Paredes M and Esteller M: Cancer epigenetics reaches mainstream oncology. Nature Med 17: 330-339, 2011.
30. Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Rev Genetics 8: 286-298, 2007.
31. Murata A, Baba Y, Watanabe M, Shigaki H, Miyake K, Ishimoto T, Iwatsuki M, Iwagami S, Sakamoto Y, Miyamoto Y, Yoshida N, Nosho K and Baba H: Methylation levels of LINE1 in primary lesion and matched metastatic lesions of colorectal cancer. Br J Cancer 109: 408-415, 2013.
32. Hur K, Cejas P, Feliu J, Moreno-Rubio J, Burgos E, Boland CR and Goel A: Hypomethylation of long interspersed nuclear element-1 (LINE1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut 63: 635-646, 2014.
33. Matsunoki A, Kawakami K, Kotake M, Kaneko M, Kitamura H, Ooi A, Watanabe G and Minamoto T: LINE1 methylation shows little intra-patient heterogeneity in primary and synchronous metastatic colorectal cancer. BMC Cancer 12: 574, 2012.
34. Antelo M, Balaguer F, Shia J, Shen Y, Hur K, Moreira L, Cuatrecasas M, Bujanda L, Giraldez MD, Takahashi M, Cabanne A, Barugel ME, Arnold M, Roca EL, Andreu M, Castellvi-Bel S, Llor X, Jover R, Castells A, Boland CR and Goel A: A high degree of LINE1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One 7: e45357, 2012.
35. Sunami E, de Maat M, Vu A, Turner RR and Hoon DS: LINE1 hypomethylation during primary colon cancer progression. PLoS One 6: e18884, 2011.
36. Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F, Warbritton AR, Latendresse JR, Kovalchuk I, Beland FA and Pogribny IP: Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle 6: 2010-2018, 2007.
37. Cole SR, Young GP, Esterman A, Cadd B and Morcom J: A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 10: 117-122, 2003.